Molecular Therapy - Nucleic Acids (MTNA)

Molecular Therapy Molecular Therapy is the leading journal for research in the areas of gene transfer, vector development and design, stem cell manipulation, development of gene-, peptide-, protein-, oligonucleotide-, and cell-based therapeutics to correct genetic and acquired diseases, vaccine development, pre-clinical target validation, safety/efficacy studies, and clinical trials. Molecular Therapy is dedicated to promoting the sciences in genetics, medicine, and biotechnology. Publishing important peer-reviewed research and cutting-edge reviews and commentaries, the journal continues to attract the best material in the field. Molecular Therapy's 2022 impact factor is 12.4. To accommodate the rapid growth of Molecular Therapy, articles will be submitted and published in one of the following subsections (for section editors, please see the editorial board page): Biomarker and therapeutic target identification Cell therapy Clinical gene and cell therapies Epigenome editing Genome editing Immunotherapy Molecular diagnostics and imaging Non-viral gene therapy RNA therapies Small-molecule therapies Vaccine development Viral gene therapy

Molecular Therapy - Nucleic Acids (MTNA) is :-

• International, Peer-Reviewed, Open Access, Refereed, biomedical engineering (Engineering and Technology, medical biology , Online , Yearly Journal

• UGC Approved, ISSN Approved: P-ISSN E-ISSN: 2162-2531, Established: 2012, Impact Factor: 6.5
• Does Not Provide Crossref DOI

• Not indexed in Scopus, WoS, DOAJ, PubMed, UGC CARE